TrialArthritis research & therapy2022

A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritis.

Rubén Burgos-Vargas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.